Rona Therapeutics has licensed an investigational RNAi candidate silencing ALK7 (ACVR1C) to Roche, with up to $100 million upfront and near-term milestones and a further $1.06 billion tied to development and commercial milestones. ALK7 is predominantly expressed in adipose tissue, and its suppression is intended to reduce visceral and ectopic fat while preserving lean mass. The approach depends on an extrahepatic delivery platform, extending RNAi therapeutics beyond their established liver-centric territory.
Key Points
- ALK7 silencing targets adipose tissue to reduce visceral and ectopic fat
- Mechanism aims to preserve lean mass alongside fat loss
- Extrahepatic RNAi delivery extends gene silencing beyond liver targets
Longevity Analysis
Visceral and ectopic fat drive insulin resistance, chronic inflammatory signaling and cardiometabolic risk far more than total body weight, making tissue-selective fat reduction a more meaningful endpoint than scale weight alone. Preservation of skeletal muscle matters because lean mass underwrites glucose disposal, metabolic rate, and functional independence across the later decades — the principal unresolved concern with current incretin-based weight loss. A durable, adipose-directed intervention would shift the question from how much weight is lost to which tissue is lost, and whether hormonal signaling and energy handling improve as a consequence.
Original published by LT Wire.